Literature DB >> 22017641

Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin.

Duyen A Ngo1, Banu Aygun, Idowu Akinsheye, Jane S Hankins, Ishir Bhan, Hong Y Luo, Martin H Steinberg, David H K Chui.   

Abstract

Compound heterozygotes for sickle haemoglobin (HbS) and hereditary persistence of fetal haemoglobin (HPFH) have high fetal haemoglobin (HbF) levels but few, if any, sickle cell disease-related complications. We studied 30 cases of HbS-HPFH (types 1 and 2), confirmed by molecular analysis, and report the haematological features and change in HbF levels over time. These results were compared to those of patients with sickle cell anaemia or HbS-β(0) thalassaemia, including a subgroup of patients carrying the XmnI polymorphism, known to be associated with elevated HbF. Among the HbS-HPFH patients, HbF level was 50-90% during infancy and declined steeply within the first few years of life, stabilizing between ages 3 and 5years, at approximately 30%. Mean HbF of individuals age 5 or older was 31±3%, average haemoglobin concentration was 130±10g/l and average mean corpuscular volume (MCV) was 75±4 fl. Univariate and multivariate regression analyses significantly associated HbF with age, haemoglobin concentration, and MCV (P<0·001). There was a strong inverse association between HbF and age (r=-0·9, P<0·001). Despite having a much higher HbF level, patients with HbS-HPFH have a similar age-related pattern of HbF decline and associations as patients with sickle cell anaemia or HbS-β(0) thalassaemia.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017641      PMCID: PMC6605093          DOI: 10.1111/j.1365-2141.2011.08916.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  34 in total

Review 1.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

3.  Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.

Authors:  Patrick T McGann; Omar Niss; Min Dong; Anu Marahatta; Thad A Howard; Tomoyuki Mizuno; Adam Lane; Theodosia A Kalfa; Punam Malik; Charles T Quinn; Russell E Ware; Alexander A Vinks
Journal:  Am J Hematol       Date:  2019-06-12       Impact factor: 10.047

Review 4.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

5.  The population dynamics of hemoglobins A, A2, F and S in the context of the hemoglobinopathies HbS and α-thalassemia in Kenyan infants.

Authors:  Alex W Macharia; Sophie Uyoga; Carolyne Ndila; Gideon Nyutu; Johnstone Makale; Metrine Tendwa; Emily Nyatichi; John Ojal; Sarah Atkinson; Thomas N Williams
Journal:  Haematologica       Date:  2018-11-22       Impact factor: 9.941

Review 6.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

7.  Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.

Authors:  Fabrizia Urbinati; Phillip W Hargrove; Sabine Geiger; Zulema Romero; Jennifer Wherley; Michael L Kaufman; Roger P Hollis; Christopher B Chambers; Derek A Persons; Donald B Kohn; Andrew Wilber
Journal:  Exp Hematol       Date:  2015-02-12       Impact factor: 3.084

Review 8.  Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment.

Authors:  Gibran Ali; Muhammad Akram Tariq; Kamran Shahid; Fridoon Jawad Ahmad; Javed Akram
Journal:  Gene Ther       Date:  2020-04-30       Impact factor: 5.250

9.  Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.

Authors:  Christian Brendel; Swaroopa Guda; Raffaele Renella; Daniel E Bauer; Matthew C Canver; Young-Jo Kim; Matthew M Heeney; Denise Klatt; Jonathan Fogel; Michael D Milsom; Stuart H Orkin; Richard I Gregory; David A Williams
Journal:  J Clin Invest       Date:  2016-09-06       Impact factor: 14.808

Review 10.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.